

BIOSPECIFICS TECHNOLOGIES CORP

Form 8-K

June 13, 2016

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **June 13, 2016**

BIOSPECIFICS TECHNOLOGIES CORP.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction
of incorporation)

001-34236

(Commission
File Number)

11-3054851

(IRS Employer
Identification No.)

35 Wilbur Street

Lynbrook, NY

(Address of principal executive offices)

11563

(Zip Code)

Registrant's telephone number, including area code: **516.593.7000**

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Introductory Comment

Throughout this Current Report on Form 8-K, the terms we, us, our and Company refer to BioSpecifics Technologies Corp.

Item 8.01. Other Events

On June 13, 2016, BioSpecifics announced top-line results from a placebo-controlled, double-blinded Phase II clinical trial of collagenase clostridium histolyticum (CCH) for the treatment of human lipoma.

A press release regarding the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

Exhibit Description

99.1 Press Release dated June 13, 2016

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 13, 2016

BioSpecifics Technologies Corp.

By: /s/ Thomas L. Wegman

Name: Thomas L. Wegman

Title: President

3

EXHIBIT INDEX

Exhibit **Description**
No.

99.1 Press Release dated June 13, 2016

4